Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers

Purpose This study aimed to evaluate the safety and pharmacokinetic (PK) profiles of HLX07, a novel, recombinant, humanized anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced solid cancers who had failed standard therapy or for whom no standard therapy was available. Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Ming-Mo, Ho, Ching-Liang, Lin, Hsuan-Yu, Zhu, Yunting, Zhang, Xiaodi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426222/
https://www.ncbi.nlm.nih.gov/pubmed/33713216
http://dx.doi.org/10.1007/s10637-021-01099-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426222/
https://www.ncbi.nlm.nih.gov/pubmed/33713216
http://dx.doi.org/10.1007/s10637-021-01099-1

Ejemplares similares